Nayla Chaijale, Ph.D.
Affiliations: | Drexel University College of Medicine, Philadelphia, PA, United States |
Area:
neurobiology of eatingGoogle:
"Nayla Chaijale"Mean distance: 17.34 (cluster 19) | S | N | B | C | P |
Parents
Sign in to add mentorKenny J. Simansky | grad student | 2010 | Drexel Medical School | |
(Regulation of feeding by the parabrachial nucleus: A model for studying the mu -opioid receptor system.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Hauser RA, Barkay H, Fernandez HH, et al. (2024) Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study. Journal of Clinical Psychopharmacology. 44: 386-396 |
Chaijale NN, Aloyo VJ, Simansky KJ. (2013) The stereoisomer (+)-naloxone potentiates G-protein coupling and feeding associated with stimulation of mu opioid receptors in the parabrachial nucleus. Journal of Psychopharmacology (Oxford, England). 27: 302-11 |
Valentino RJ, Chaijale N, Snyder K, et al. (2013) The Locus Coeruleus, Stress, Opioids and Behavioral Flexibility Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 160 |
Chaijale NN, Aloyo VJ, Simansky KJ. (2008) A naloxonazine sensitive (mu1 receptor) mechanism in the parabrachial nucleus modulates eating. Brain Research. 1240: 111-8 |
Cucchiaro G, Chaijale N, Commons KG. (2006) The locus coeruleus nucleus as a site of action of the antinociceptive and behavioral effects of the nicotinic receptor agonist, epibatidine. Neuropharmacology. 50: 769-76 |
Cucchiaro G, Chaijale N, Commons KG. (2005) The dorsal raphe nucleus as a site of action of the antinociceptive and behavioral effects of the alpha4 nicotinic receptor agonist epibatidine. The Journal of Pharmacology and Experimental Therapeutics. 313: 389-94 |